Black Diamond Therapeutics CFO Thomas Leggett resigns; Fang Ni named interim CFO

Black Diamond Therapeutics, Inc.

CFO Thomas Leggett resigned effective Nov 16, 2021, not due to any disagreement; will stay until Dec 3 for transition.
Board appointed Fang Ni, Pharm.D., Chief Business Officer, as Interim CFO and principal financial officer effective Nov 19.
Erika Jones, VP Finance and Corporate Controller, appointed principal accounting officer effective same date.
Ni's base salary $388,100, eligible for up to 40% annual bonus; severance includes lump sum equal to base salary.
Resignation and appointments are part of planned succession; no family relationships or conflicts reported.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Thomas Leggett

Chief Financial Officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2021-11-16
Successor: Fang Ni
Filed: November 22, 2021, 6:59 PM ET

On November 16, 2021, Thomas Leggett resigned from his position as Chief Financial Officer (principal financial and accounting officer) of Black Diamond Therapeutics, Inc. (the “ Company ”) effective immediately.

Appointed

Erika Jones

principal accounting officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2021-11-19
Filed: November 22, 2021, 6:59 PM ET

Effective November 19, 2021, the Board appointed Erika Jones, the Company’s Vice President, Finance and Corporate Controller, as principal accounting officer until a successor is appointed.

Appointed (interim)

Fang Ni

Interim Chief Financial Officer

BDTX · Black Diamond Therapeutics, Inc.

Effective: 2021-11-19
Filed: November 22, 2021, 6:59 PM ET

Effective November 19, 2021, the Board of Directors of the Company (the “ Board ”) appointed Fang Ni, Pharm. D., the Company’s Chief Business Officer, as Interim Chief Financial Officer and principal financial officer until a successor is appointed.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Leggett resigned as Chief Financial Officer at Black Diamond Therapeutics, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On November 16, 2021, Thomas Leggett resigned from his position as Chief Financial Officer (principal financial and accounting officer) of Black Diamond Therapeutics, Inc. (the “ Company ”) effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Erika Jones was appointed as principal accounting officer at Black Diamond Therapeutics, Inc..

Action: appointed
Role: principal accounting officer

Exact text from the filing

Effective November 19, 2021, the Board appointed Erika Jones, the Company’s Vice President, Finance and Corporate Controller, as principal accounting officer until a successor is appointed.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Fang Ni was appointed as Interim Chief Financial Officer at Black Diamond Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

Effective November 19, 2021, the Board of Directors of the Company (the “ Board ”) appointed Fang Ni, Pharm. D., the Company’s Chief Business Officer, as Interim Chief Financial Officer and principal financial officer until a successor is appointed.

View on SEC.gov

Black Diamond Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-142198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.